Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine plus tetrabenazine for oromandibular dyskinesia
IRCT20220623055257N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in oromandibular dystonia (OMD) comparing Mirtazapine plus tetrabenazine with Placebo plus tetrabenazine (2 arms). Primary endpoints: AIMS score change, Abnormal movement severity and amount and 1 more. Started Jan 2025; status: completed.
02
Drugs
mirtazapinetetrabenazine
03
Conditions
oromandibular dystonia (OMD)
Beyond the preview
Go deeper on IRCT20220623055257N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220623055257N2.